Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.

@article{Lapadula2012BiosimilarsIR,
  title={Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.},
  author={Giovanni Lapadula and Gianfranco Ferraccioli},
  journal={Clinical and experimental rheumatology},
  year={2012},
  volume={30 4 Suppl 73},
  pages={S102-6}
}
Rheumatoid arthritis (RA) societal costs are high because the disease may cause not only restricted joint mobility, chronic pain, fatigue, and functional disability, but also psychological distress. Direct health care costs represent about one-fourth of all costs and are prevalently represented by in-patient care expenditures. The introduction of biologics disease-modifying anti-rheumatic drugs (B-DMARDs), has really changed the perspectives of the patients not fully responding to conventional… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Biosimilar medicines - Review.

The International journal of risk & safety in medicine • 2016

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Scientific considerations in demonstrating biosimilarity to a reference product: draft guidance February 2012

FOOD, DRUG ADMINISTRATION
Available from URL: http://www. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM291128.pdf. Accessed April 4. • 2012

KAVANAUGH A: New biologic agents in patients with rheumatoid arthritis

R FLEISCHMANN, AF WELLS
Update to Rheum Dis Clin NA 2011; • 2011

MITTENDORF T et al.: Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings

T KIRCHHOFF, J RUOF
Rheumatology (Oxford) • 2011

New biologic agents in patients with rheumatoid arthritis

R FLEISCHMANN, AF WELLS, A KAVANAUGH
Update to Rheum Dis Clin NA • 2011

Similar Papers

Loading similar papers…